Today, we announced that the European Commission has granted marketing authorization in the EU for a treatment for eligible adults with moderate to severe hidradenitis suppurativa (HS). Visit our website to learn more. bit.ly/4iIDRoB
1
2
267
We're excited to join the hematology community at #ASH26! Explore the data we'll be presenting and follow along for updates from the meeting. bit.ly/3WgK2aJ
1
1
387
Read our press release to learn about our Q3 financial results and business updates, including progress across our portfolio. bit.ly/3UTF7Mo
1
256
Learn more from Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development, on the progress being made across our GI oncology portfolio at #ESMO26. bit.ly/4yDiOs9
1
341
Incyte shared new data from our KRAS G12D and TGFβR2xPD-1 programs in PDAC and MSS CRC at #ESMO26. Learn more. bit.ly/3WMBt7v
3
544
Despite advances, pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancers to treat.
Understanding KRAS G12D mutations is central to advancing more targeted research for these patients. Learn more. #SolveOn bit.ly/4iaUDfX
264
We’ve announced a clinical trial collaboration with @Genmab for patients with first-line metastatic colorectal cancer (CRC) harboring a KRAS G12D mutation. Learn more. bit.ly/4BpE07x
6
746
⏰ #ESMO26 begins tomorrow!
We're looking forward to sharing new data from our solid tumor portfolio, including research in pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable colorectal cancer (MSS CRC). Read our press release to learn more. bit.ly/4siy248
2
297
From our booth to sessions at the #EADVCongress, it was exciting to connect with the global dermatology community and share the latest in inflammation and autoimmunity.
2
411
There’s more to vitiligo than what appears on the skin.
A deeper understanding of the condition and the experiences of people living with it is essential to continued progress. Learn more about Incyte’s work to address patient needs through science and innovation. bit.ly/4AERnjV
1
295
At this year’s #EADVCongress we’ll join researchers, clinicians and advocates from around the world to discuss how a deeper understanding of immune-mediated skin conditions can help advance research and patient care. bit.ly/4xUWYA7
1
245
An important milestone for people living with fibrodysplasia ossificans progressiva (FOP). The @FDA has approved an oral ALK2 inhibitor developed by Incyte and licensed to @mirumpharma for worldwide development and commercialization. Learn more in the press release. bit.ly/4rxVfza





